Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target
Given the early clinical data on Checkmate Pharmaceuticals Inc’s (NASDAQ: CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities.
